Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NeoTCR P1

Next Previous
Drug Profile

NeoTCR P1

Alternative Names: Autologous gene-edited TCR T cell product - PACT Pharma; Neoantigen-targeted T cells therapy - PACT Pharma; Neoepitope specific adoptive T cell therapy - PACT Pharma; NeoTCR-P1

Latest Information Update: 18 Apr 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PACT Pharma
  • Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Bladder cancer; Breast cancer; Head and neck cancer; Lung cancer; Malignant melanoma; Ovarian cancer; Prostate cancer; Solid tumours

Most Recent Events

  • 18 Apr 2023 Phase-I clinical trials in Bladder cancer (Combination therapy, Late-stage disease, Second-line therapy or greater, Metastatic disease) in USA (Parenteral) (PACT Pharma pipeline, April 2023)
  • 18 Apr 2023 Phase-I clinical trials in Bladder cancer (Late-stage disease, Monotherapy, Metastatic disease, Second-line therapy or greater) in USA (Parenteral) (PACT Pharma pipeline, April 2023)
  • 18 Apr 2023 Phase-I clinical trials in Breast cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater, Metastatic disease) in USA (Parenteral) (PACT Pharma pipeline, April 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top